News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lyfetec, Inc. Has Inked Contract With Intellect Laboratories, Inc. for Drug Screening Products and Services



3/23/2009 10:39:25 AM

FT LAUDERDALE, FL--(Marketwire - March 23, 2009) - LYFETEC, Inc. (PINKSHEETS: TSHL) listed under new CUSIP 55084L 10 6, has finalized its exclusive license contract with Intellect Laboratories, Inc. for a comprehensive line of drug testing and screening products and services. The line will be enhanced by Intellect and private branded such that LyfeTec will be a sole source licensee.

The products and services will soon be offered by LyfeTec to specific existing and new distributors in several countries. Two different product categories exist within the set of twelve (12) tests, one set targeted for over the counter markets and another focused at professional and corporate use. A unique packaging and tracking system with associated identity protection software makes the LyfeTec products unique in the industry and an attractive complement to its growing line.

The tests consist of eleven (11) specific drug screening tests that use saliva and urine to accurately and definitively detect drug presence, offering immediate results to the user. Results are provided in a new way to assure strict confidentiality for the user. For a small additional price, the specimen(s) can be sent into one of LyfeTec's affiliate labs for independent verification of results in writing -- an important unfulfilled need in this industry. LyfeTec believes that this dual results approach coupled with the first-to-market confidentiality software controls will increase customer reliance on the LyfeTec products thereby providing a considerable competitive advantage to the company.

The last product in the set consists of a unique screening kit for uncovering tobacco use. This product is seen by LyfeTec marketing as an important one because insurance companies, plastic surgeons, employers, parents and so forth need to reliably know if an individual uses tobacco. As with all of the screening products described, the tobacco screening test provides instant, confidential results.

Safe Harbor Act Disclaimer: Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks, and uncertainties and actual results could differ from those discussed. This material is information only and is not an offer or solicitation to buy or sell the securities.


Contact:

pmatteis@lyfetec.com
Phone 954-772-2640
Fax 954-772-2643

Officers:
Phil Matteis
Chairman and CEO

Steven Cohen
Executive Vice President


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES